Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
FEIBA STAR
NCT02764489Phase 3Completed
- Sponsor
- Takeda
- Start
- Feb 2019
- Primary completion
- Dec 2021
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 3
01
Overview
Phase 3, randomised, open-label trial of anti-inhibitor coagulant complex in hemophilia A and hemophilia B (HB) (2 arms), sponsored by Takeda. Primary endpoints: Number of Participants With Any Treatment Emergent Adverse Event (TEAE), Number of Participants With Any Hypersensitivity Reaction and 3 more. Started Feb 2019; status: completed.
02
Drugs
anti-inhibitor coagulant complex
03
Conditions
hemophilia Ahemophilia B (HB)
Beyond the preview
Go deeper on NCT02764489.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02764489.